** U.S.-listed shares of German drugmaker CureVac 5CV.DE, CVAC.O rise 15.4% to $3.23 premarket

** European Patent Office upheld a CVAC mRNA patent after it was challenged by rival BioNTech 22UAy.DE, co said on Thursday

** A German court will decide on July 1 if BioNTech infringed this patent

** The dispute is part of a larger ongoing patent battle between CureVac and BioNTech over mRNA tech used in COVID-19 vaccines

** CVAC fell 8.2% in the last 12 months

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))